Nasomaris 1 Mg/Ml (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. By binding to alpha‑receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which decreases blood flow, reduces mucosal edema, and opens the nasal airway.

The specific dosing regimen for Nasomaris 1 Mg/Ml is determined by the prescribing healthcare professional. Typically, the product is administered as a few sprays into each nostril, but the exact number of sprays and frequency should follow the prescriber’s instructions.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Nasomaris.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s team will respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Nasomaris contains Xylometazoline, an alpha‑adrenergic agonist similar to oxymetazoline. Both provide rapid relief of congestion, but Xylometazoline may have a slightly longer duration of action. Choice between products often depends on clinician preference, patient tolerance, and local availability.

Nasomaris should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product after the expiration date printed on the label.

Nasomaris is a nasal spray solution. The user tilts the head slightly forward, inserts the nozzle into a nostril, and depresses the pump to deliver the recommended number of sprays. The same procedure is repeated for the other nostril if instructed by the prescriber.

Serious risks, though uncommon, include severe nasal bleeding, allergic reactions such as rash or anaphylaxis, marked hypertension, tachycardia, and rebound congestion (rhinitis medicamentosa) after prolonged use. Any signs of these reactions require immediate medical attention.

Nasomaris should be avoided in individuals with known hypersensitivity to Xylometazoline or any excipients, in children under 6 years unless directed by a physician, and in patients with uncontrolled hypertension, severe cardiovascular disease, or those already using other nasal decongestants.